|
| Press Releases |
|
 |
|
| Wednesday, September 15, 2021 |
|
|
Hua and Sinopharm Announced Supply Chain Strategic Cooperation |
| On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099). more info >> |
|
| Thursday, August 19, 2021 |
|
|
华领医药公布2021年中期业绩 |
| 华领医药（「公司」，香港联交所股份代号：2552.HK），今天宣布公司及其附属公司截至2021年6月30日止，6个月（「报告期」）的综合业绩。 more info >> |
|
|
華領醫藥公佈2021年中期業績 |
| 華領醫藥（「公司」，香港聯交所股份代號：2552.HK），今天宣佈公司及其附屬公司截至2021年6月30日止，6個月（「報告期」）的綜合業績。 more info >> |
|
|
Hua Medicine Announces 2021 Interim Results |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period"). more info >> |
|
| Friday, April 23, 2021 |
|
|
华领医药糖尿病首创新药多扎格列艾汀NDA获NMPA受理！为全球首个葡萄糖激酶激活剂 |
| 华领医药（「公司」，香港联交所股份代号：2552.HK），今天宣布，糖尿病首创新药多扎格列艾汀( dorzagliatin)递交的NDA申请已获国家药品监督管理局（NMPA）新药审评中心（CDE）受理。多扎格列艾汀成为全球范围内首个提交新药上市申请的葡萄糖激酶激活剂类（GKA）糖尿病治疗药物，并有望成为在中国首先上市的全球首创新药（FIC）。 more info >> |
|
|
華領醫藥糖尿病首創新藥多扎格列艾汀NDA獲NMPA受理！為全球首個葡萄糖激酶激活劑 |
| 華領醫藥（「公司」，香港聯交所股份代號：2552.HK），今天宣布，糖尿病首創新藥多扎格列艾汀(dorzagliatin)遞交的NDA申請已獲國家藥品監督管理局（NMPA）新藥審評中心（CDE）受理。 more info >> |
|
|
Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). more info >> |
|
| Friday, March 19, 2021 |
|
|
华领医药公布2020年全年业绩 |
| 华领医药（「公司」，香港联交所股份代号：2552.HK），今天宣布公司及其附属公司截至2020年12月31日止经审核的全年业绩（「报告期」）。 more info >> |
|
|
華領醫藥公佈2020年全年業績 |
| 華領醫藥（「公司」，香港聯交所股份代號：2552.HK），今天宣佈公司及其附屬公司截至2020年12月31日止經審核的全年業績（「報告期」）。 more info >> |
|
|
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission |
| Hua Medicine (2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
AsiaMedic and Sunway launch new Medical Diagnostic Imaging Centre in Novena
Feb 24, 2025 18:39: JST
|
|
|
Hong Kong rated as leading sustainable business hub
Feb 24, 2025 18:13 HKT/SGT
|
|
|
Blackrock Silver Steps Out and Hits Multiple +1 kg/t AgEq Intercepts in First Assays from Resource Expansion Program at Tonopah West
Feb 24, 2025 18:09 HKT/SGT
|
|
|
A Bold Experiment: Red Notice Coin (RNC) Drops a Game-Changer in the Crypto World
Feb 24, 2025 15:00: JST
|
|
|
蜜雪集团招股进行时：IP建设步入快车道 红杉中国、高瓴等担纲基石
Feb 24, 2025 14:10 HKT/SGT
|
|
|
蜜雪集團招股進行時：IP建設步入快車道 紅杉中國、高瓴等擔綱基石
Feb 24, 2025 14:08 HKT/SGT
|
|
|
Nissin Foods (Hong Kong) Charity Fund Supports Elite Athletes from The Education University of Hong Kong for the Third Consecutive Year
Feb 24, 2025 13:47 HKT/SGT
|
|
|
日清食品（香港）慈善基金连续第三年支持香港教育大学精英运动员
Feb 24, 2025 13:37 HKT/SGT
|
|
|
日清食品（香港）慈善基金連續第三年支持香港教育大學精英運動員
Feb 24, 2025 13:25 HKT/SGT
|
|
|
日清食品（香港）慈善基金連續第三年支持香港教育大學精英運動員
Feb 24, 2025 13:19 HKT/SGT
|
|
|
A Bold Experiment: Red Notice Coin (RNC) Drops a Game-Changer in the Crypto World
Feb 24, 2025 13:00 HKT/SGT
|
|
|
HKIRA 11th IR Awards 2025 now open for nomination
Feb 24, 2025 12:52 HKT/SGT
|
|
|
2025年第十一屆投資者關係大獎現正接受公眾提名
Feb 24, 2025 12:30 HKT/SGT
|
|
|
數字化及全球化打造行業領導力 全球現製飲品龍頭蜜雪集團招股中
Feb 24, 2025 12:21 HKT/SGT
|
|
|
数字化及全球化打造行业领导力 全球现制饮品龙头蜜雪集团招股中
Feb 24, 2025 12:14 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
